Elastography Imaging Market Size to Expand at 7.2% CAGR through 2032 - Persistence Market Research

The elastography imaging market has witnessed remarkable growth in recent years, driven by the increasing demand for non-invasive diagnostic tools across various medical specialties. Elastography, an advanced imaging technique used to assess tissue stiffness, is emerging as a vital tool for diagnosing and monitoring diseases such as chronic liver conditions, breast cancer, and musculoskeletal disorders. With a projected market value of US$7.5 billion by 2032, up from US$4.6 billion in 2025, elastography imaging is expected to grow at a compound annual growth rate (CAGR) of 7.2% from 2025 to 2032.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35570

Market Size and Trends Analysis

The elastography imaging market is poised for significant growth, fueled by rising healthcare demands and a global shift towards non-invasive diagnostic technologies. The non-invasive nature of elastography, especially in evaluating liver fibrosis, breast cancer, and musculoskeletal disorders, has made it a preferred diagnostic tool among clinicians. The market is expected to experience substantial expansion, driven by advancements in imaging modalities, supportive government policies, and growing awareness among healthcare professionals.

Key trends influencing the market include the rising burden of chronic liver diseases, such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Hepatitis, as well as the increasing incidence of breast cancer, which is pushing for more effective diagnostic and monitoring tools. Moreover, the technology's integration with Artificial Intelligence (AI) and its growing use in personalized medicine and multi-modality platforms are expected to further propel market growth.

Key Industry Highlights

Leading Region: North America is expected to hold a dominant share of around 35.7% of the elastography imaging market in 2025. The region benefits from favorable reimbursement policies, government initiatives, and widespread adoption of advanced medical imaging technologies. The United States, in particular, has established clear procedural codes for elastography procedures, which have facilitated its widespread clinical use.

Fastest-Growing Region: Europe is anticipated to witness the fastest market growth due to expanding cancer screening programs and supportive government initiatives aimed at early disease detection. The demand for elastography in assessing liver diseases and breast cancer is expected to drive this growth.

Dominant Modality: Ultrasound elastography is projected to hold a dominant market share of 70.1% in 2025. The popularity of ultrasound is driven by its portability, affordability, and the ability to provide real-time results. As a result, many hospitals are incorporating elastography as an add-on feature to existing ultrasound machines, significantly reducing capital investment.

Leading Application: General imaging, including liver, thyroid, and musculoskeletal assessments, is expected to account for nearly 33.8% of the elastography market share in 2025. This widespread use of elastography across various organs and diseases demonstrates its versatility and efficiency in clinical settings.

Market Dynamics

Driver - Rising Burden of Chronic Liver Disease and Breast Cancer

The primary driver of the elastography imaging market is the increasing prevalence of chronic liver diseases, such as hepatitis B, hepatitis C, and NAFLD, which require precise staging of liver fibrosis. Elastography imaging, especially shear-wave elastography, has gained popularity for its ability to monitor liver stiffness non-invasively, reducing the need for costly and uncomfortable biopsies. In Europe, for example, elastography is now part of routine monitoring in several hospitals, reducing biopsy rates by up to 40%.

Similarly, the rising incidence of breast cancer is spurring the demand for elastography imaging. According to the World Health Organization (WHO), breast cancer was responsible for an estimated 670,000 deaths in 2022, highlighting the need for early diagnosis and effective monitoring. Elastography provides an effective method for differentiating benign from malignant lesions, especially in dense breast tissue where mammography is less reliable.

Restraint - Technical Challenges in Obese Patients

Despite its widespread adoption, elastography imaging faces certain challenges, particularly when it comes to patients with larger body types or atypical anatomies. Excess adipose tissue in obese patients can weaken ultrasound signals and hinder accurate stiffness measurements. A study published in Hepatology Communications in 2023 revealed that liver stiffness measurements failed in nearly 15% of obese patients. Similarly, challenges in breast imaging include uneven stress distribution due to large or dense breast tissue. While new probes and AI-based algorithms are being developed to address these issues, the technology's reliability in these patient groups remains a key limitation.

Opportunity - Multi-Modality Platforms in Oncology

An exciting opportunity in the elastography imaging market is the development of multi-modality platforms that combine elastography with other imaging technologies like Magnetic Resonance Elastography (MRE). This combination allows clinicians to validate stiffness measurements across different modalities, resulting in higher diagnostic accuracy and reliability. Multi-modality elastography is particularly useful in oncology, where distinguishing between benign and malignant lesions remains a challenge. Moreover, the rise of personalized medicine provides an opportunity for elastography to play a critical role in dynamically tracking disease progression in individual patients.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/elastography-imaging-market.asp

Category-Wise Analysis

Modality Insights

The elastography imaging market is segmented into two primary modalities: ultrasound and magnetic resonance. Ultrasound elastography is expected to dominate the market with a 70.1% share in 2025. Its affordability, portability, and ease of integration into existing clinical workflows make it the preferred choice for most healthcare providers. Ultrasound-based elastography systems are often add-ons to conventional ultrasound machines, making it a cost-effective solution for hospitals.

On the other hand, Magnetic Resonance Elastography (MRE) is gaining traction due to its ability to provide higher reproducibility and whole-organ coverage, particularly in liver disease diagnostics. MRE delivers more consistent stiffness measurements across the entire liver, making it valuable for clinical trials and research where repeatability and standardization are critical.

Application Insights

By application, the elastography imaging market is segmented into general imaging, hepatology, breast, cardiology, nephrology, orthopedics, and musculoskeletal imaging. The general imaging segment is expected to hold a substantial 33.8% market share in 2025, as elastography allows for multi-organ assessments, which enhances its utility across diverse medical specialties.

In breast imaging, elastography is emerging as a key tool for early cancer detection, particularly in regions where mammography is less effective, such as Europe and Asia Pacific. Countries like Japan and India have incorporated elastography into screening protocols for women under 40, as mammography often misses tumors in young women.

Regional Insights

North America remains the largest market for elastography imaging, driven by clear reimbursement frameworks, Medicare coverage, and fast adoption across hospitals. The U.S. healthcare system is investing heavily in elastography, particularly in liver disease diagnostics, which is expected to continue growing in the coming years.

Europe has a varied adoption pattern influenced by country-specific reimbursement policies. France, for instance, has widely adopted transient elastography as the standard for chronic liver disease monitoring, while Germany and the U.K. are incorporating elastography into ultrasound systems for cost efficiency.

In the Asia Pacific region, China is leading the growth in elastography imaging, driven by the high prevalence of hepatitis and metabolic liver diseases. India is also expanding elastography usage, especially in private healthcare settings, although access remains limited in rural areas.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35570

Competitive Landscape

The elastography imaging market is highly competitive, with several established players dominating the high-end hospital segment. Major companies like Canon Medical Systems Corporation, FUJIFILM Corporation, GE Healthcare, and Siemens AG are leading the market with their advanced ultrasound and MRI systems that incorporate elastography capabilities. Additionally, smaller companies are focusing on niche applications, particularly for liver health, to maintain competitiveness.

Key Industry Developments

In August 2025, Sonic Incytes Medical Corp. received FDA clearance for its point-of-care ultrasound elastography device, Velacur ONE, offering improved portability and user experience.

In April 2025, Royal Philips launched the Elevate Platform, an upgrade for its EPIQ Elite ultrasound system, which enables remote support and system troubleshooting, enhancing the utility of elastography imaging.

Future Outlook

The future of the elastography imaging market looks promising, with rapid advancements in technology, an expanding range of clinical applications, and increasing adoption across different regions. The market is set to benefit from innovations like AI integration, multi-modality systems, and enhanced imaging protocols, making elastography an even more integral tool in disease diagnostics and monitoring. As healthcare systems continue to prioritize non-invasive, cost-effective diagnostic methods, elastography is positioned to become a core technology in clinical settings worldwide.

Read More Related Reports:

Short Bowel Syndrome Market https://www.persistencemarketresearch.com/market-research/short-bowel-syndrome-market.asp
Adult Hemoglobinopathy Testing Market https://www.persistencemarketresearch.com/market-research/adult-hemoglobinopathy-testing-market.asp
External Fixators Market https://www.persistencemarketresearch.com/market-research/external-fixators-market.asp
Postoperative Pain Management Market https://www.persistencemarketresearch.com/market-research/postoperative-pain-management-market.asp
Clinical Electronic Thermometer Market https://www.persistencemarketresearch.com/market-research/clinical-electronic-thermometer-market.asp

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.